Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Other Non-Current Liabilities (2016 - 2017)

Historic Other Non-Current Liabilities for Cytosorbents (CTSO) over the last 4 years, with Q2 2017 value amounting to $1.0 million.

  • Cytosorbents' Other Non-Current Liabilities fell 4213.27% to $1.0 million in Q2 2017 from the same period last year, while for Jun 2017 it was $1.0 million, marking a year-over-year decrease of 4213.27%. This contributed to the annual value of $1.8 million for FY2016, which is 1072.16% up from last year.
  • Latest data reveals that Cytosorbents reported Other Non-Current Liabilities of $1.0 million as of Q2 2017, which was down 4213.27% from $1.7 million recorded in Q1 2017.
  • Cytosorbents' 5-year Other Non-Current Liabilities high stood at $3.0 million for Q4 2014, and its period low was $1.0 million during Q2 2017.
  • For the 4-year period, Cytosorbents' Other Non-Current Liabilities averaged around $1.9 million, with its median value being $1.7 million (2016).
  • In the last 5 years, Cytosorbents' Other Non-Current Liabilities crashed by 4512.25% in 2015 and then surged by 1072.16% in 2016.
  • Cytosorbents' Other Non-Current Liabilities (Quarter) stood at $3.0 million in 2014, then plummeted by 45.12% to $1.6 million in 2015, then grew by 10.72% to $1.8 million in 2016, then tumbled by 42.23% to $1.0 million in 2017.
  • Its Other Non-Current Liabilities was $1.0 million in Q2 2017, compared to $1.7 million in Q1 2017 and $1.8 million in Q4 2016.